Your English writing platform
Discover LudwigExact(60)
The primary efficacy end point was progression-free survival 6 months.
Secondary efficacy end points were progression-free survival and overall survival.
The primary efficacy end point of the trial is Major Adverse Limb Event–Free Survival.
In total, 14 patients (34.1%) had SD for more than 6 months, which met our preplanned primary efficacy end point.
The primary efficacy end point was stroke or systemic embolism; the safety end point we studied was major hemorrhage.
The primary efficacy end point was vein occlusion during follow-up.
The primary efficacy end point was dialysis-free survival through day 21.
The primary efficacy end point is death or nonfatal myocardial infarction 30 days after enrollment.
Three efficacy end points were tested for noninferiority.
The key secondary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke.
The encouraging efficacy end points suggest that the further study of bevacizumab with chemoradiotherapy is warranted.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com